HUTCHMED (China) Limited (0013.HK)
HKD 23.0
(-0.22%)
HKD 23.0
(-0.22%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 837.99 Million USD | 96.52% |
| 2022 | 426.4 Million USD | 19.73% |
| 2021 | 356.12 Million USD | 56.21% |
| 2020 | 227.97 Million USD | 11.27% |
| 2019 | 204.89 Million USD | -4.31% |
| 2018 | 214.1 Million USD | -11.23% |
| 2017 | 241.2 Million USD | 11.63% |
| 2016 | 216.08 Million USD | 21.25% |
| 2015 | 178.2 Million USD | 94.09% |
| 2014 | 91.81 Million USD | 99.72% |
| 2013 | 45.97 Million USD | -76.47% |
| 2012 | 195.39 Million USD | 17.05% |
| 2011 | 166.92 Million USD | 24.1% |
| 2010 | 134.5 Million USD | 21.18% |
| 2009 | 110.99 Million USD | 27.62% |
| 2008 | 86.97 Million USD | 33.58% |
| 2007 | 65.1 Million USD | 29.1% |
| 2006 | 50.43 Million USD | 33.21% |
| 2005 | 37.86 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 152.84 Million USD | 0.18% |
| 2024 Q2 | 152.84 Million USD | 0.0% |
| 2023 Q1 | 266.43 Million USD | 137.51% |
| 2023 FY | 837.99 Million USD | 96.52% |
| 2023 Q4 | 152.56 Million USD | 0.0% |
| 2023 Q3 | 152.56 Million USD | -42.74% |
| 2023 Q2 | 266.43 Million USD | 0.0% |
| 2022 Q2 | 101.02 Million USD | 0.0% |
| 2022 Q3 | 112.18 Million USD | 11.04% |
| 2022 FY | 426.4 Million USD | 19.73% |
| 2022 Q4 | 112.18 Million USD | 0.0% |
| 2022 Q1 | 101.02 Million USD | 1.65% |
| 2021 Q4 | 99.38 Million USD | 0.0% |
| 2021 Q3 | 99.38 Million USD | 31.1% |
| 2021 FY | 356.12 Million USD | 56.21% |
| 2021 Q2 | 75.8 Million USD | -7.05% |
| 2021 Q1 | 81.55 Million USD | 34.57% |
| 2020 Q3 | 60.6 Million USD | 9.8% |
| 2020 FY | 227.97 Million USD | 11.27% |
| 2020 Q1 | 51.57 Million USD | -3.33% |
| 2020 Q2 | 55.19 Million USD | 7.03% |
| 2020 Q4 | 60.6 Million USD | 0.0% |
| 2019 Q2 | 50.02 Million USD | -4.1% |
| 2019 Q1 | 52.16 Million USD | -1.77% |
| 2019 FY | 204.89 Million USD | -4.31% |
| 2019 Q4 | 53.34 Million USD | 8.1% |
| 2019 Q3 | 49.34 Million USD | -1.36% |
| 2018 Q3 | 58.81 Million USD | 17.97% |
| 2018 FY | 214.1 Million USD | -11.23% |
| 2018 Q2 | 49.85 Million USD | -4.75% |
| 2018 Q1 | 52.33 Million USD | -8.68% |
| 2018 Q4 | 53.1 Million USD | -9.7% |
| 2017 FY | 241.2 Million USD | 11.63% |
| 2017 Q4 | 57.3 Million USD | 0.0% |
| 2017 Q1 | 63.29 Million USD | 13.46% |
| 2017 Q3 | 57.3 Million USD | -9.45% |
| 2017 Q2 | 63.29 Million USD | 0.0% |
| 2016 FY | 216.08 Million USD | 21.25% |
| 2016 Q4 | 55.78 Million USD | 0.0% |
| 2016 Q3 | 55.78 Million USD | 6.74% |
| 2016 Q2 | 52.25 Million USD | 0.0% |
| 2016 Q1 | 52.25 Million USD | -7.15% |
| 2015 Q1 | 41.24 Million USD | 22.9% |
| 2015 FY | 178.2 Million USD | 94.09% |
| 2015 Q4 | 56.28 Million USD | 0.15% |
| 2015 Q3 | 56.19 Million USD | 36.26% |
| 2015 Q2 | 41.24 Million USD | 0.0% |
| 2014 Q2 | 15.16 Million USD | 0.0% |
| 2014 Q1 | 15.16 Million USD | 216.88% |
| 2014 Q4 | 33.55 Million USD | 20.18% |
| 2014 FY | 91.81 Million USD | 99.72% |
| 2014 Q3 | 27.92 Million USD | 84.15% |
| 2013 Q1 | 8.77 Million USD | 43.29% |
| 2013 Q2 | 8.77 Million USD | 0.0% |
| 2013 Q3 | 14.2 Million USD | 61.89% |
| 2013 Q4 | 4.78 Million USD | -66.32% |
| 2013 FY | 45.97 Million USD | -76.47% |
| 2012 FY | 195.39 Million USD | 17.05% |
| 2012 Q4 | 6.12 Million USD | 0.0% |
| 2012 Q3 | 6.12 Million USD | 0.0% |
| 2011 FY | 166.92 Million USD | 24.1% |
| 2010 FY | 134.5 Million USD | 21.18% |
| 2009 FY | 110.99 Million USD | 27.62% |
| 2008 FY | 86.97 Million USD | 33.58% |
| 2007 FY | 65.1 Million USD | 29.1% |
| 2006 FY | 50.43 Million USD | 33.21% |
| 2005 FY | 37.86 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -223.354% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 92.041% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -1317.982% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -6.904% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | 12.826% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | 20.421% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | 50.895% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -3.571% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -105.968% |
| SSY Group Limited | 6.46 Billion HKD | 87.034% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -29.238% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | 42.908% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 99.69% |